Greenwich LifeSciences, Inc.
GLSI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001799788
In the last 90 days, Greenwich LifeSciences, Inc. insiders filed 3 open-market purchases and 0 sales; 57 institutions reported holding it in 13F filings for Q2 2026, worth $39.6M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Greenwich LifeSciences, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q2 2023
- Shares held
- 537.4K
- −91.4K (−14.5%) vs. Q2 2023
- Total value
- $4.75M
- −$1.31M (−21.7%) vs. Q2 2023
- New holders
- 2
- 4 more added
- Sold out
- 1
- 9 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GLSI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 57 | $39.6M |
| Q1 2026 | 64 | $41.1M |
| Q4 2025 | 50 | $27.9M |
| Q3 2025 | 51 | $12.1M |
| Q2 2025 | 51 | $11.2M |
| Q1 2025 | 46 | $11.1M |
| Q4 2024 | 42 | $13.3M |
| Q3 2024 | 39 | $16.4M |
| Q2 2024 | 34 | $17.6M |
| Q1 2024 | 31 | $12.9M |
| Q4 2023 | 27 | $5.64M |
| Q3 2023 | 24 | $4.75M |
| Q2 2023 | 23 | $6.06M |
| Q1 2023 | 28 | $11.4M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 21 | $7.21M |
| Q2 2022 | 34 | $8.74M |
| Q1 2022 | 34 | $18.3M |
| Q4 2021 | 35 | $19.4M |
| Q3 2021 | 36 | $31.9M |
| Q2 2021 | 30 | $36.4M |
| Q1 2021 | 19 | $8.90M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Greenwich LifeSciences, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 9 | $0 | 0.00% | −97−91.5% | Reduced |
| UBS Group AG | 1 | $9 | 0.00% | −227−99.6% | Reduced |
| JPMorgan Chase & Co | 4 | $35 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 38 | $336 | 0.00% | +13+52.0% | Added |
| AdvisorNet Financial, Inc | 50 | $442 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 50 | $442 | 0.00% | 00.0% | Unchanged |
| North Star Investment Management Corp. | 51 | $451 | 0.00% | 00.0% | Unchanged |
| Geneos Wealth Management Inc. | 88 | $778 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 93 | $822 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 280 | $2.48K | 0.00% | −477−63.0% | Reduced |
| Founders Capital Management | 500 | $4.42K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,296 | $11.5K | 0.00% | +68+5.5% | Added |
| Qube Research & Technologies Ltd | 1,310 | $11.6K | 0.00% | +1,310 | New |
| Newbridge Financial Services Group, Inc. | 1,500 | $13.3K | 0.01% | 00.0% | Unchanged |
| Bank of America Corp | 3,369 | $29.8K | 0.00% | −1,691−33.4% | Reduced |
| Squarepoint Ops LLC | 10,970 | $97.0K | 0.00% | +10,970 | New |
| State Street Corp | 13,002 | $114.9K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 19,155 | $169.3K | 0.00% | −16,193−45.8% | Reduced |
| Gsa Capital Partners LLP | 45,850 | $405.0K | 0.03% | +12,441+37.2% | Added |
| Geode Capital Management, LLC | 46,092 | $407.6K | 0.00% | +6,159+15.4% | Added |
| Renaissance Technologies LLC | 54,298 | $480.0K | 0.00% | −24,902−31.4% | Reduced |
| BlackRock Inc. | 55,990 | $495.0K | 0.00% | −1,585−2.8% | Reduced |
| Ameriprise Financial Inc | 63,404 | $560.5K | 0.00% | −4,788−7.0% | Reduced |
| Vanguard Group Inc | 219,953 | $1.94M | 0.00% | −62,262−22.1% | Reduced |
| HRT Financial LP | 0 | $0 | 0.00% | −10,136−100.0% | Sold out |